U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C12H13ClN4
Molecular Weight 248.711
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PYRIMETHAMINE

SMILES

CCC1=C(C(N)=NC(N)=N1)C2=CC=C(Cl)C=C2

InChI

InChIKey=WKSAUQYGYAYLPV-UHFFFAOYSA-N
InChI=1S/C12H13ClN4/c1-2-9-10(11(14)17-12(15)16-9)7-3-5-8(13)6-4-7/h3-6H,2H2,1H3,(H4,14,15,16,17)

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/9554869

Pyrimethamine, sold under the trade name Daraprim, is one of the folic acid antagonists that is used as an antimalarial or with a sulfonamide to treat toxoplasmosis. In addition it was approved in Chemoprophylaxis of Malaria. However, resistance to pyrimethamine is prevalent worldwide. It is not suitable as a prophylactic agent for travelers to most areas. Pyrimethamine is well absorbed with peak levels occurring between 2 to 6 hours following administration. It is eliminated slowly and has a plasma half-life of approximately 96 hours. Pyrimethamine is 87% bound to human plasma proteins. Pyrimethamine acts by selectively inhibiting malarial dihydrofolate reductase-thymidylate synthase and the rationale for its therapeutic action is based on the differential requirement between host and parasite for nucleic acid precursors involved in growth. This activity is highly selective against plasmodia and Toxoplasma gondii. Pyrimethamine possesses blood schizonticidal and some tissue schizonticidal activity against malaria parasites of humans. The action of pyrimethamine against Toxoplasma gondii is greatly enhanced when used in conjunction with sulfonamides.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
1.5 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
DARAPRIM

Approved Use

Treatment of Toxoplasmosis: DARAPRIM is indicated for the treatment of toxoplasmosis when used conjointly with a sulfonamide, since synergism exists with this combination. Treatment of Acute Malaria: DARAPRIM is also indicated for the treatment of acute malaria. It should not be used alone to treat acute malaria. Fast-acting schizonticides such as chloroquine or quinine are indicated and preferable for the treatment of acute malaria. However, conjoint use of DARAPRIM with a sulfonamide (e.g., sulfadoxine) will initiate transmission control and suppression of susceptible strains of plasmodia. Chemoprophylaxis of Malaria: DARAPRIM is indicated for the chemoprophylaxis of malaria due to susceptible strains of plasmodia. However, resistance to pyrimethamine is prevalent worldwide. It is not suitable as a prophylactic agent for travelers to most areas.

Launch Date

-5.34556803E11
Curative
DARAPRIM

Approved Use

Treatment of Toxoplasmosis: DARAPRIM is indicated for the treatment of toxoplasmosis when used conjointly with a sulfonamide, since synergism exists with this combination. Treatment of Acute Malaria: DARAPRIM is also indicated for the treatment of acute malaria. It should not be used alone to treat acute malaria. Fast-acting schizonticides such as chloroquine or quinine are indicated and preferable for the treatment of acute malaria. However, conjoint use of DARAPRIM with a sulfonamide (e.g., sulfadoxine) will initiate transmission control and suppression of susceptible strains of plasmodia. Chemoprophylaxis of Malaria: DARAPRIM is indicated for the chemoprophylaxis of malaria due to susceptible strains of plasmodia. However, resistance to pyrimethamine is prevalent worldwide. It is not suitable as a prophylactic agent for travelers to most areas.

Launch Date

-5.34556803E11
Preventing
DARAPRIM

Approved Use

Treatment of Toxoplasmosis: DARAPRIM is indicated for the treatment of toxoplasmosis when used conjointly with a sulfonamide, since synergism exists with this combination. Treatment of Acute Malaria: DARAPRIM is also indicated for the treatment of acute malaria. It should not be used alone to treat acute malaria. Fast-acting schizonticides such as chloroquine or quinine are indicated and preferable for the treatment of acute malaria. However, conjoint use of DARAPRIM with a sulfonamide (e.g., sulfadoxine) will initiate transmission control and suppression of susceptible strains of plasmodia. Chemoprophylaxis of Malaria: DARAPRIM is indicated for the chemoprophylaxis of malaria due to susceptible strains of plasmodia. However, resistance to pyrimethamine is prevalent worldwide. It is not suitable as a prophylactic agent for travelers to most areas.

Launch Date

-5.34556803E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2.059 μg/mL
50 mg 1 times / day steady-state, oral
dose: 50 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: Zidovudine
PYRIMETHAMINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
502.9 μg × h/mL
50 mg 1 times / day steady-state, oral
dose: 50 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: Zidovudine
PYRIMETHAMINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
190.56 h
50 mg 1 times / day steady-state, oral
dose: 50 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: Zidovudine
PYRIMETHAMINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
13%
PYRIMETHAMINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1.625 g single, oral
Overdose
Dose: 1.625 g
Route: oral
Route: single
Dose: 1.625 g
Sources: Page: p.19
healthy, 1
n = 1
Health Status: healthy
Age Group: 1
Sex: M
Population Size: 1
Sources: Page: p.19
Disc. AE: Vomiting, Convulsions...
AEs leading to
discontinuation/dose reduction:
Vomiting
Convulsions (severe)
Cyanosis
Sources: Page: p.19
625 mg single, oral
Overdose
Dose: 625 mg
Route: oral
Route: single
Dose: 625 mg
Sources: Page: p.19
healthy, 1
n = 1
Health Status: healthy
Age Group: 1
Population Size: 1
Sources: Page: p.19
Disc. AE: Convulsions, Respiratory failure...
AEs leading to
discontinuation/dose reduction:
Convulsions
Respiratory failure (grade 5)
Sources: Page: p.19
1.2 g single, oral
Overdose
Dose: 1.2 g
Route: oral
Route: single
Dose: 1.2 g
Sources: Page: p.19
healthy, 2
n = 1
Health Status: healthy
Age Group: 2
Sex: M
Population Size: 1
Sources: Page: p.19
Disc. AE: Cyanosis, Vomiting...
AEs leading to
discontinuation/dose reduction:
Cyanosis
Vomiting (severe)
Convulsions
Apnoea
Haematemesis
Cardiac failure (grade 5)
Sources: Page: p.19
400 mg single, oral
Overdose
Dose: 400 mg
Route: oral
Route: single
Dose: 400 mg
Sources: Page: p.19
healthy, 2
n = 1
Health Status: healthy
Age Group: 2
Sex: F
Population Size: 1
Sources: Page: p.19
Disc. AE: Convulsions, Vomiting...
AEs leading to
discontinuation/dose reduction:
Convulsions (severe)
Vomiting
Cyanosis
Collapse
Sources: Page: p.19
625 mg single, oral
Overdose
Dose: 625 mg
Route: oral
Route: single
Dose: 625 mg
Sources: Page: p.19
healthy, 3
n = 1
Health Status: healthy
Age Group: 3
Sex: F
Population Size: 1
Sources: Page: p.19
Disc. AE: Convulsions, Unconsciousness...
AEs leading to
discontinuation/dose reduction:
Convulsions (grade 5)
Unconsciousness (grade 5)
Sources: Page: p.19
300 mg single, oral (min)
Overdose
Dose: 300 mg
Route: oral
Route: single
Dose: 300 mg
Sources: Page: p.3
unhealthy
Health Status: unhealthy
Condition: Toxoplasmosis
Sources: Page: p.3
Disc. AE: Convulsions, Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Convulsions
Abdominal pain
Nausea
Vomiting (severe)
Excitability
Respiratory depression (grade 5)
Circulatory collapse (grade 5)
Sources: Page: p.3
75 mg 1 times / day multiple, oral (max)
Recommended
Dose: 75 mg, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg, 1 times / day
Sources: Page: p.2
unhealthy
Health Status: unhealthy
Condition: Toxoplasmosis
Sources: Page: p.2
Disc. AE: Folate deficiency...
AEs leading to
discontinuation/dose reduction:
Folate deficiency
Sources: Page: p.2
AEs

AEs

AESignificanceDosePopulation
Cyanosis Disc. AE
1.625 g single, oral
Overdose
Dose: 1.625 g
Route: oral
Route: single
Dose: 1.625 g
Sources: Page: p.19
healthy, 1
n = 1
Health Status: healthy
Age Group: 1
Sex: M
Population Size: 1
Sources: Page: p.19
Vomiting Disc. AE
1.625 g single, oral
Overdose
Dose: 1.625 g
Route: oral
Route: single
Dose: 1.625 g
Sources: Page: p.19
healthy, 1
n = 1
Health Status: healthy
Age Group: 1
Sex: M
Population Size: 1
Sources: Page: p.19
Convulsions severe
Disc. AE
1.625 g single, oral
Overdose
Dose: 1.625 g
Route: oral
Route: single
Dose: 1.625 g
Sources: Page: p.19
healthy, 1
n = 1
Health Status: healthy
Age Group: 1
Sex: M
Population Size: 1
Sources: Page: p.19
Convulsions Disc. AE
625 mg single, oral
Overdose
Dose: 625 mg
Route: oral
Route: single
Dose: 625 mg
Sources: Page: p.19
healthy, 1
n = 1
Health Status: healthy
Age Group: 1
Population Size: 1
Sources: Page: p.19
Respiratory failure grade 5
Disc. AE
625 mg single, oral
Overdose
Dose: 625 mg
Route: oral
Route: single
Dose: 625 mg
Sources: Page: p.19
healthy, 1
n = 1
Health Status: healthy
Age Group: 1
Population Size: 1
Sources: Page: p.19
Apnoea Disc. AE
1.2 g single, oral
Overdose
Dose: 1.2 g
Route: oral
Route: single
Dose: 1.2 g
Sources: Page: p.19
healthy, 2
n = 1
Health Status: healthy
Age Group: 2
Sex: M
Population Size: 1
Sources: Page: p.19
Convulsions Disc. AE
1.2 g single, oral
Overdose
Dose: 1.2 g
Route: oral
Route: single
Dose: 1.2 g
Sources: Page: p.19
healthy, 2
n = 1
Health Status: healthy
Age Group: 2
Sex: M
Population Size: 1
Sources: Page: p.19
Cyanosis Disc. AE
1.2 g single, oral
Overdose
Dose: 1.2 g
Route: oral
Route: single
Dose: 1.2 g
Sources: Page: p.19
healthy, 2
n = 1
Health Status: healthy
Age Group: 2
Sex: M
Population Size: 1
Sources: Page: p.19
Haematemesis Disc. AE
1.2 g single, oral
Overdose
Dose: 1.2 g
Route: oral
Route: single
Dose: 1.2 g
Sources: Page: p.19
healthy, 2
n = 1
Health Status: healthy
Age Group: 2
Sex: M
Population Size: 1
Sources: Page: p.19
Cardiac failure grade 5
Disc. AE
1.2 g single, oral
Overdose
Dose: 1.2 g
Route: oral
Route: single
Dose: 1.2 g
Sources: Page: p.19
healthy, 2
n = 1
Health Status: healthy
Age Group: 2
Sex: M
Population Size: 1
Sources: Page: p.19
Vomiting severe
Disc. AE
1.2 g single, oral
Overdose
Dose: 1.2 g
Route: oral
Route: single
Dose: 1.2 g
Sources: Page: p.19
healthy, 2
n = 1
Health Status: healthy
Age Group: 2
Sex: M
Population Size: 1
Sources: Page: p.19
Collapse Disc. AE
400 mg single, oral
Overdose
Dose: 400 mg
Route: oral
Route: single
Dose: 400 mg
Sources: Page: p.19
healthy, 2
n = 1
Health Status: healthy
Age Group: 2
Sex: F
Population Size: 1
Sources: Page: p.19
Cyanosis Disc. AE
400 mg single, oral
Overdose
Dose: 400 mg
Route: oral
Route: single
Dose: 400 mg
Sources: Page: p.19
healthy, 2
n = 1
Health Status: healthy
Age Group: 2
Sex: F
Population Size: 1
Sources: Page: p.19
Vomiting Disc. AE
400 mg single, oral
Overdose
Dose: 400 mg
Route: oral
Route: single
Dose: 400 mg
Sources: Page: p.19
healthy, 2
n = 1
Health Status: healthy
Age Group: 2
Sex: F
Population Size: 1
Sources: Page: p.19
Convulsions severe
Disc. AE
400 mg single, oral
Overdose
Dose: 400 mg
Route: oral
Route: single
Dose: 400 mg
Sources: Page: p.19
healthy, 2
n = 1
Health Status: healthy
Age Group: 2
Sex: F
Population Size: 1
Sources: Page: p.19
Convulsions grade 5
Disc. AE
625 mg single, oral
Overdose
Dose: 625 mg
Route: oral
Route: single
Dose: 625 mg
Sources: Page: p.19
healthy, 3
n = 1
Health Status: healthy
Age Group: 3
Sex: F
Population Size: 1
Sources: Page: p.19
Unconsciousness grade 5
Disc. AE
625 mg single, oral
Overdose
Dose: 625 mg
Route: oral
Route: single
Dose: 625 mg
Sources: Page: p.19
healthy, 3
n = 1
Health Status: healthy
Age Group: 3
Sex: F
Population Size: 1
Sources: Page: p.19
Abdominal pain Disc. AE
300 mg single, oral (min)
Overdose
Dose: 300 mg
Route: oral
Route: single
Dose: 300 mg
Sources: Page: p.3
unhealthy
Health Status: unhealthy
Condition: Toxoplasmosis
Sources: Page: p.3
Convulsions Disc. AE
300 mg single, oral (min)
Overdose
Dose: 300 mg
Route: oral
Route: single
Dose: 300 mg
Sources: Page: p.3
unhealthy
Health Status: unhealthy
Condition: Toxoplasmosis
Sources: Page: p.3
Excitability Disc. AE
300 mg single, oral (min)
Overdose
Dose: 300 mg
Route: oral
Route: single
Dose: 300 mg
Sources: Page: p.3
unhealthy
Health Status: unhealthy
Condition: Toxoplasmosis
Sources: Page: p.3
Nausea Disc. AE
300 mg single, oral (min)
Overdose
Dose: 300 mg
Route: oral
Route: single
Dose: 300 mg
Sources: Page: p.3
unhealthy
Health Status: unhealthy
Condition: Toxoplasmosis
Sources: Page: p.3
Circulatory collapse grade 5
Disc. AE
300 mg single, oral (min)
Overdose
Dose: 300 mg
Route: oral
Route: single
Dose: 300 mg
Sources: Page: p.3
unhealthy
Health Status: unhealthy
Condition: Toxoplasmosis
Sources: Page: p.3
Respiratory depression grade 5
Disc. AE
300 mg single, oral (min)
Overdose
Dose: 300 mg
Route: oral
Route: single
Dose: 300 mg
Sources: Page: p.3
unhealthy
Health Status: unhealthy
Condition: Toxoplasmosis
Sources: Page: p.3
Vomiting severe
Disc. AE
300 mg single, oral (min)
Overdose
Dose: 300 mg
Route: oral
Route: single
Dose: 300 mg
Sources: Page: p.3
unhealthy
Health Status: unhealthy
Condition: Toxoplasmosis
Sources: Page: p.3
Folate deficiency Disc. AE
75 mg 1 times / day multiple, oral (max)
Recommended
Dose: 75 mg, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg, 1 times / day
Sources: Page: p.2
unhealthy
Health Status: unhealthy
Condition: Toxoplasmosis
Sources: Page: p.2
Overview

Overview

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
inconclusive [Activation 10 uM]
inconclusive [Activation 39.8107 uM]
inconclusive [Activation 5.0119 uM]
inconclusive [Activation 7.9433 uM]
inconclusive [Activation >10 uM]
no [Activation >10 uM]
no
no
weak [IC50 200.1 uM]
yes [IC50 0.131 uM]
yes [IC50 1.8 uM]
yes [IC50 4.55 uM]
yes [IC50 45.1 uM]
yes
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
PubMed

PubMed

TitleDatePubMed
In vitro cultivation of Cryptosporidium parvum and screening for anticryptosporidial drugs.
1990 Aug
Resolution of acute renal failure in toxoplasmic encephalitis despite continuance of sulfadiazine.
1990 Jul-Aug
Pneumocystis carinii dihydrofolate reductase used to screen potential antipneumocystis drugs.
1991 Jul
Evaluation of the effect of drugs on the cyst form of Toxoplasma gondii.
1991 Jul
Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis.
1991 May
Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs.
1992 Sep
Antituberculosis activity of certain antifungal and antihelmintic drugs.
1999
Expression and characterization of recombinant human-derived Pneumocystis carinii dihydrofolate reductase.
2000 Nov
Inhibition of growth of Pneumocystis carinii by lactoferrins alone and in combination with pyrimethamine, clarithromycin and minocycline.
2000 Oct
Dapsone-mediated agranulocytosis: risks, possible mechanisms and prevention.
2001 Apr 12
Structural studies on bioactive compounds. 34. Design, synthesis, and biological evaluation of triazenyl-substituted pyrimethamine inhibitors of Pneumocystis carinii dihydrofolate reductase.
2001 Aug 2
Activity of gatifloxacin alone or in combination with pyrimethamine or gamma interferon against Toxoplasma gondii.
2001 Jan
[Malaria vector control in Cameroon: past, present, future. Reflections].
2001 Jul
A trial of proguanil-dapsone in comparison with sulfadoxine-pyrimethamine for the clearance of Plasmodium falciparum infections in Tanzania.
2001 Jul-Aug
Pitfalls in imaging Hodgkin's disease with computed tomography and positron emission tomography using fluorine-18-fluorodeoxyglucose.
2001 May
[Adverse effects of Disulone; results of the France pharmacovigilance inquiry. Regional Centers of Pharmacovigilance].
2001 May-Jun
Inhibition of glutathione S-transferases by antimalarial drugs possible implications for circumventing anticancer drug resistance.
2002 Feb 10
Antiprotozoals effective in vitro against the scuticociliate fish pathogen Philasterides dicentrarchi.
2002 Jun 3
Effect of immunomodulator daraprim on potentiation of vaccine protection of leishmania major in BALB/c mice.
2003 Mar
Pyrimethamine (2,4-diamino-5-p-chlorophenyl-6-ethylpyrimidine) induces apoptosis of freshly isolated human T lymphocytes, bypassing CD95/Fas molecule but involving its intrinsic pathway.
2005 Dec
Prediction of genotoxicity of chemical compounds by statistical learning methods.
2005 Jun
Hydrogen-bonding patterns in pyrimethaminium dinitrate.
2005 Oct
HIV as an additional risk factors for anaemia in pregnancy: evidence from primary care level in Ibadan, Southwestern Nigeria.
2005 Sep
Therapeutic efficacy of sulphadoxine-pyrimethamine and chloroquine for the treatment of uncomplicated malaria in pregnancy in Burkina Faso.
2006 Jun 15
Pyrimethamine treatment does not ameliorate lymphoproliferation or autoimmune disease in MRL/lpr-/- mice or in patients with autoimmune lymphoproliferative syndrome.
2007 Dec
In silico prediction of pregnane X receptor activators by machine learning approaches.
2007 Jan
Impact of placental Plasmodium falciparum malaria on pregnancy and perinatal outcome in sub-Saharan Africa: I: introduction to placental malaria.
2007 Jun
Suppression of telomerase activity by pyrimethamine: implication to cancer.
2007 Oct
Pyrimethamine induces apoptosis of melanoma cells via a caspase and cathepsin double-edged mechanism.
2008 Jul 1
Factors related to compliance to anti-malarial drug combination: example of amodiaquine/sulphadoxine-pyrimethamine among children in rural Senegal.
2009 Jun 4
Antifolate activity of pyrimethamine enhances temozolomide-induced cytotoxicity in melanoma cells.
2009 May
Active case detection, treatment of falciparum malaria with combined chloroquine and sulphadoxine/pyrimethamine and vivax malaria with chloroquine and molecular markers of anti-malarial resistance in the Republic of Vanuatu.
2010 Apr 6
Evaluation of the effect of pyrimethamine, an anti-malarial drug, on HIV-1 replication.
2010 Nov
Toxoplasma gondii: inhibitory activity and encystation effect of securinine and pyrrolidine derivatives on Toxoplasma growth.
2011 Feb
Antiplasmodial and analgesic activities of Clausena anisata.
2012 Mar
Palmitate increases the susceptibility of cells to drug-induced toxicity: an in vitro method to identify drugs with potential contraindications in patients with metabolic disease.
2012 Oct
Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target.
2012 Oct 16
In vitro and in vivo characterization of the antimalarial lead compound SSJ-183 in Plasmodium models.
2013
Synthesis, characterization and antimalarial activity of quinoline-pyrimidine hybrids.
2013 Jan 1
A facile three-component [3+2]-cycloaddition for the regioselective synthesis of highly functionalised dispiropyrrolidines acting as antimycobacterial agents.
2013 Mar 1
Patents

Sample Use Guides

Toxoplasmosis: The adult starting dose is 50 to 75 mg of the drug daily, together with 1 to 4 g daily of a sulfonamide of the sulfapyrimidine type, e.g., sulfadoxine. This dosage is ordinarily continued for 1 to 3 weeks, depending on the response of the patient and tolerance to therapy. The dosage may then be reduced to about one half that previously given for each drug and continued for an additional 4 to 5 weeks. The pediatric dosage of DARAPRIM (PYRIMETHAMINE) is 1 mg/kg/day divided into 2 equal daily doses; after 2 to 4 days this dose may be reduced to one half and continued for approximately 1 month. The usual pediatric sulfonamide dosage is used in conjunction with DARAPRIM. Treatment of Acute Malaria: at a dosage of 25 mg daily for 2 days with a sulfonamide will initiate transmission control and suppression of non-falciparum malaria. The adult dosage for acute malaria is 50 mg for 2 days; children 4 through 10 years old may be given 25 mg daily for 2 days. In any event, clinical cure should be followed by the once-weekly regimen described below for chemoprophylaxis. Regimens which include suppression should be extended through any characteristic periods of early recrudescence and late relapse, i.e., for at least 10 weeks in each case. For Chemoprophylaxis of Malaria: Adults and pediatric patients over 10 years — 25 mg (1 tablet) once weekly. Children 4 through 10 years — 12.5 mg (1/2 tablet) once weekly. Infants and children under 4 years — 6.25 mg (1/4 tablet) once weekly.
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: The cytotoxic influence of Pyrimethamine on prostate cell line was investigated using an in vitro colometric assay. Cytotoxicity analysis of pyrimethamine revealed a dose-dependent fashion. An apoptotic influence of pyrimethamine was also confirmed by data obtained from TUNEL assay. Dose-dependent inhibitory effect on matrix metalloproteinases (MMP) was seen in pyrimethamine. A potent inhibitory effect of pyrimethamine was also established by data achieved from TRAPeze telomerase detection kit.
Unknown
Name Type Language
PYRIMETHAMINE
EP   GREEN BOOK   INN   JAN   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INN  
Official Name English
PYRIMETHAMINE [MART.]
Common Name English
PYRIMETHAMINE [WHO-IP]
Common Name English
FANSIDAR COMPONENT PYRIMETHAMINE
Common Name English
RP-4753
Code English
2,4-DIAMINO-5-(P-CHLOROPHENYL)-6-ETHYLPYRIMIDINE
Common Name English
PYRIMETHAMINE [VANDF]
Common Name English
CHLORIDINE
Common Name English
DARAPRIM
Brand Name English
Pyrimethamine [WHO-DD]
Common Name English
PYRIMETHAMINE COMPONENT OF FANSIDAR
Common Name English
WR-2978
Code English
PYRIMETHAMINE [JAN]
Common Name English
PYRIMETHAMINE [USP MONOGRAPH]
Common Name English
PYRIMETHAMINE [IARC]
Common Name English
pyrimethamine [INN]
Common Name English
PYRIMETHAMINE [MI]
Common Name English
PYRIMETHAMINE [GREEN BOOK]
Common Name English
GNF-PF-5586
Code English
TCMDC-125860
Code English
PYRIMETHAMINE [EP MONOGRAPH]
Common Name English
PYRIMETHAMINE [USP-RS]
Common Name English
PYRIMETHAMINUM [WHO-IP LATIN]
Common Name English
2,4-PYRIMIDINEDIAMINE, 5-(4-CHLOROPHENYL)-6-ETHYL-
Systematic Name English
NSC-3061
Code English
PYRIMETHAMINE [ORANGE BOOK]
Common Name English
Classification Tree Code System Code
LIVERTOX NBK548044
Created by admin on Fri Dec 16 16:52:47 UTC 2022 , Edited by admin on Fri Dec 16 16:52:47 UTC 2022
NDF-RT N0000000191
Created by admin on Fri Dec 16 16:52:47 UTC 2022 , Edited by admin on Fri Dec 16 16:52:47 UTC 2022
NDF-RT N0000000191
Created by admin on Fri Dec 16 16:52:47 UTC 2022 , Edited by admin on Fri Dec 16 16:52:47 UTC 2022
WHO-ATC P01BD51
Created by admin on Fri Dec 16 16:52:47 UTC 2022 , Edited by admin on Fri Dec 16 16:52:47 UTC 2022
NDF-RT N0000175934
Created by admin on Fri Dec 16 16:52:47 UTC 2022 , Edited by admin on Fri Dec 16 16:52:47 UTC 2022
WHO-ESSENTIAL MEDICINES LIST 6.5.3.1 (SUL/PYR)
Created by admin on Fri Dec 16 16:52:47 UTC 2022 , Edited by admin on Fri Dec 16 16:52:47 UTC 2022
FDA ORPHAN DRUG 232206
Created by admin on Fri Dec 16 16:52:47 UTC 2022 , Edited by admin on Fri Dec 16 16:52:47 UTC 2022
EPA PESTICIDE CODE 600071
Created by admin on Fri Dec 16 16:52:47 UTC 2022 , Edited by admin on Fri Dec 16 16:52:47 UTC 2022
WHO-ESSENTIAL MEDICINES LIST 6.5.4
Created by admin on Fri Dec 16 16:52:47 UTC 2022 , Edited by admin on Fri Dec 16 16:52:47 UTC 2022
IARC Pyrimethamine
NCI_THESAURUS C271
Created by admin on Fri Dec 16 16:52:47 UTC 2022 , Edited by admin on Fri Dec 16 16:52:47 UTC 2022
NCI_THESAURUS C2153
Created by admin on Fri Dec 16 16:52:47 UTC 2022 , Edited by admin on Fri Dec 16 16:52:47 UTC 2022
WHO-ATC P01BF04
Created by admin on Fri Dec 16 16:52:47 UTC 2022 , Edited by admin on Fri Dec 16 16:52:47 UTC 2022
CFR 21 CFR 520.2215
Created by admin on Fri Dec 16 16:52:47 UTC 2022 , Edited by admin on Fri Dec 16 16:52:47 UTC 2022
WHO-VATC QP51AX51
Created by admin on Fri Dec 16 16:52:47 UTC 2022 , Edited by admin on Fri Dec 16 16:52:47 UTC 2022
WHO-ATC P01BD01
Created by admin on Fri Dec 16 16:52:47 UTC 2022 , Edited by admin on Fri Dec 16 16:52:47 UTC 2022
Code System Code Type Description
MERCK INDEX
M9368
Created by admin on Fri Dec 16 16:52:47 UTC 2022 , Edited by admin on Fri Dec 16 16:52:47 UTC 2022
PRIMARY Merck Index
MESH
D011739
Created by admin on Fri Dec 16 16:52:47 UTC 2022 , Edited by admin on Fri Dec 16 16:52:47 UTC 2022
PRIMARY
DAILYMED
Z3614QOX8W
Created by admin on Fri Dec 16 16:52:47 UTC 2022 , Edited by admin on Fri Dec 16 16:52:47 UTC 2022
PRIMARY
RS_ITEM_NUM
1589007
Created by admin on Fri Dec 16 16:52:47 UTC 2022 , Edited by admin on Fri Dec 16 16:52:47 UTC 2022
PRIMARY
PUBCHEM
4993
Created by admin on Fri Dec 16 16:52:47 UTC 2022 , Edited by admin on Fri Dec 16 16:52:47 UTC 2022
PRIMARY
ChEMBL
CHEMBL36
Created by admin on Fri Dec 16 16:52:47 UTC 2022 , Edited by admin on Fri Dec 16 16:52:47 UTC 2022
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
PYRIMETHAMINE
Created by admin on Fri Dec 16 16:52:47 UTC 2022 , Edited by admin on Fri Dec 16 16:52:47 UTC 2022
PRIMARY Description: A white, crystalline powder; odourless. Solubility: Practically insoluble in water; slightly soluble in ethanol (~750 g/l) TS and acetone R. Category: Antimalarial. Storage: Pyrimethamine should be kept in a well-closed container, protected from light. Definition: Pyrimethamine contains not less than 99.0% and not more than 101.0% of C12H13ClN4, calculated with reference to the dried substance.
WIKIPEDIA
PYRIMETHAMINE
Created by admin on Fri Dec 16 16:52:47 UTC 2022 , Edited by admin on Fri Dec 16 16:52:47 UTC 2022
PRIMARY
INN
2215
Created by admin on Fri Dec 16 16:52:47 UTC 2022 , Edited by admin on Fri Dec 16 16:52:47 UTC 2022
PRIMARY
RXCUI
9010
Created by admin on Fri Dec 16 16:52:47 UTC 2022 , Edited by admin on Fri Dec 16 16:52:47 UTC 2022
PRIMARY RxNorm
CAS
58-14-0
Created by admin on Fri Dec 16 16:52:47 UTC 2022 , Edited by admin on Fri Dec 16 16:52:47 UTC 2022
PRIMARY
CHEBI
8673
Created by admin on Fri Dec 16 16:52:47 UTC 2022 , Edited by admin on Fri Dec 16 16:52:47 UTC 2022
PRIMARY
IUPHAR
4800
Created by admin on Fri Dec 16 16:52:47 UTC 2022 , Edited by admin on Fri Dec 16 16:52:47 UTC 2022
PRIMARY
DRUG BANK
DB00205
Created by admin on Fri Dec 16 16:52:47 UTC 2022 , Edited by admin on Fri Dec 16 16:52:47 UTC 2022
PRIMARY
FDA UNII
Z3614QOX8W
Created by admin on Fri Dec 16 16:52:47 UTC 2022 , Edited by admin on Fri Dec 16 16:52:47 UTC 2022
PRIMARY
EVMPD
SUB10169MIG
Created by admin on Fri Dec 16 16:52:47 UTC 2022 , Edited by admin on Fri Dec 16 16:52:47 UTC 2022
PRIMARY
NCI_THESAURUS
C788
Created by admin on Fri Dec 16 16:52:47 UTC 2022 , Edited by admin on Fri Dec 16 16:52:47 UTC 2022
PRIMARY
NSC
3061
Created by admin on Fri Dec 16 16:52:47 UTC 2022 , Edited by admin on Fri Dec 16 16:52:47 UTC 2022
PRIMARY
EPA CompTox
DTXSID9021217
Created by admin on Fri Dec 16 16:52:47 UTC 2022 , Edited by admin on Fri Dec 16 16:52:47 UTC 2022
PRIMARY
ECHA (EC/EINECS)
200-364-2
Created by admin on Fri Dec 16 16:52:47 UTC 2022 , Edited by admin on Fri Dec 16 16:52:47 UTC 2022
PRIMARY
LACTMED
Pyrimethamine
Created by admin on Fri Dec 16 16:52:47 UTC 2022 , Edited by admin on Fri Dec 16 16:52:47 UTC 2022
PRIMARY
LACTMED
Sulfadoxine and Pyrimethamine
Created by admin on Fri Dec 16 16:52:47 UTC 2022 , Edited by admin on Fri Dec 16 16:52:47 UTC 2022
PRIMARY
DRUG CENTRAL
2332
Created by admin on Fri Dec 16 16:52:47 UTC 2022 , Edited by admin on Fri Dec 16 16:52:47 UTC 2022
PRIMARY
HSDB
8042
Created by admin on Fri Dec 16 16:52:47 UTC 2022 , Edited by admin on Fri Dec 16 16:52:47 UTC 2022
PRIMARY